Discussion Diabetic ketoacidosis (DKA) is a complication commonly associated with type 1
diabetes mellitus, but may also occur with type 2 diabetes in states of relative insulin …

If not detected early, euglycemic diabetic ketoacidosis can be a serious adverse effect of
sodium–glucose cotransporter‐2 (SGLT2) inhibitors. Unfortunately, euglycemic diabetic …

Introduction and Objective: Postmarketing reports and warnings of serious adverse events
such as diabetic ketoacidosis (DKA) have raised concern regarding the safety of sodium …

BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are commonly
prescribed to manage patients with diabetes mellitus. These agents may rarely lead to the …

Since the approval of sodium-glucose cotransporter 2 (SGLT2) inhibitors by the US Food
and Drug Administration for type 2 diabetes, there have been several reports of euglycemic …

Background. Sodium glucose cotransporter-2 (SGLT2) inhibitors have been proven to be
very effective in the management of type II diabetes. These medications can cause adverse …

Euglycemic diabetic ketoacidosis (euDKA) is an uncommon condition, which is
characterized by an elevated anion gap metabolic acidosis with ketonemia/ketonuria, in the …

Background Regulatory agencies have concluded that sodium glucose cotransporter 2
(SGLT2) inhibitors lead to ketoacidosis, but published literature on this point remains …

Rationale: Diabetic ketoacidosis is a serious and potentially life-threatening acute
complication of diabetes mellitus (DM). Euglycemic diabetic ketoacidosis (eDKA) is however …

Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) have become a commonly used class
of drugs with the results from the EMPA‐REG OUTCOME study demonstrating reductions in …